2021
DOI: 10.1016/j.aohep.2020.07.008
|View full text |Cite
|
Sign up to set email alerts
|

An Integrated Review of the Hepatorenal Syndrome

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
16
0
3

Year Published

2021
2021
2023
2023

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 31 publications
(26 citation statements)
references
References 43 publications
0
16
0
3
Order By: Relevance
“…The pathophysiology of HRS-AKI is multifactorial and mostly attributed to an uncompensated hyperdynamic circulatory system, renal vasoconstriction and systematic inflammation [ 9 , 10 , 11 ]. The diagnosis of HRS-AKI is often demanding and complex due to the clinical challenge of differentiating between HRS-AKI and other causes of AKI (such as pre-renal azotemia and acute tubular necrosis (ATN)).…”
Section: Introductionmentioning
confidence: 99%
“…The pathophysiology of HRS-AKI is multifactorial and mostly attributed to an uncompensated hyperdynamic circulatory system, renal vasoconstriction and systematic inflammation [ 9 , 10 , 11 ]. The diagnosis of HRS-AKI is often demanding and complex due to the clinical challenge of differentiating between HRS-AKI and other causes of AKI (such as pre-renal azotemia and acute tubular necrosis (ATN)).…”
Section: Introductionmentioning
confidence: 99%
“…All vasoconstrictors should be combined with albumin 114 . These drugs augment systolic blood pressure and arterial volume, increasing renal perfusion, producing systemic and splanchnic vasoconstriction 115 .…”
Section: Acute Kidney Injury -Hepatorenal Syndrome (Aki-hrs) Preventi...mentioning
confidence: 99%
“…This is supported by the fact that a lower percentage of patients received a liver transplant within 90 days in the terlipressin group compared with the placebo group (23% versus 29%) with no difference in Model for End-stage Liver Disease scores between both groups. Liver transplantation is the definitive treatment for HRS (10), and other pathways of treatment, including vasopressors and plasma expanders, are generally used to bridge patients to liver transplantation. Using a treatment regimen that could potentially induce serious adverse events precluding liver transplantation is clearly a significant material risk that would need to be disclosed to patients.…”
Section: The Unattractivementioning
confidence: 99%